PURPOSE: To investigate the hypothesis that four-dimensional (4D) transcatheter intraarterial perfusion (TRIP) magnetic resonance imaging (MRI) can quantify immediate perfusion changes after radiofrequency (RF) ablation in rabbit VX2 liver tumors. MATERIALS AND METHODS: Nine New Zealand White rabbits were used to surgically implant VX2 liver tumors. During ultrasound-guided RF ablation, tumors received either a true or sham ablation. After selective catheterization of the left hepatic artery under x-ray fluoroscopy, we acquired pre- and post-RF ablation 4D TRIP MR images using 3 mL of 2.5% intraarterial gadopentetate dimeglumine. Two regions-of-interest were drawn upon each tumor to generate signal-intensity time curves. Area under the curve (AUC) was calculated to provide semiquantitative perfusion measurements that were compared using a paired t-test (α = 0.05). Ablated tissue was visually confirmed on pathology using Evans blue dye. RESULTS: Mean AUC perfusion of VX2 tumors for the true ablation group decreased by 92.0% (95% confidence interval [CI]: 83.3%-100%), from 1913 (95% CI: 1557, 2269) before RF ablation to 76.6 (95% CI: 18.4, 134.8) after RF ablation (a.u., P < 0.001). Sham-ablated tumors demonstrated no significant perfusion changes. CONCLUSION: 4D TRIP MRI can quantify liver tumor perfusion reductions in VX2 rabbits after RF ablation. This MRI technique can potentially be used to improve tumor response assessment at the time of RF ablation.
PURPOSE: To investigate the hypothesis that four-dimensional (4D) transcatheter intraarterial perfusion (TRIP) magnetic resonance imaging (MRI) can quantify immediate perfusion changes after radiofrequency (RF) ablation in rabbit VX2 liver tumors. MATERIALS AND METHODS: Nine New Zealand White rabbits were used to surgically implant VX2 liver tumors. During ultrasound-guided RF ablation, tumors received either a true or sham ablation. After selective catheterization of the left hepatic artery under x-ray fluoroscopy, we acquired pre- and post-RF ablation 4D TRIP MR images using 3 mL of 2.5% intraarterial gadopentetate dimeglumine. Two regions-of-interest were drawn upon each tumor to generate signal-intensity time curves. Area under the curve (AUC) was calculated to provide semiquantitative perfusion measurements that were compared using a paired t-test (α = 0.05). Ablated tissue was visually confirmed on pathology using Evans blue dye. RESULTS: Mean AUC perfusion of VX2 tumors for the true ablation group decreased by 92.0% (95% confidence interval [CI]: 83.3%-100%), from 1913 (95% CI: 1557, 2269) before RF ablation to 76.6 (95% CI: 18.4, 134.8) after RF ablation (a.u., P < 0.001). Sham-ablated tumors demonstrated no significant perfusion changes. CONCLUSION: 4D TRIP MRI can quantify liver tumor perfusion reductions in VX2 rabbits after RF ablation. This MRI technique can potentially be used to improve tumor response assessment at the time of RF ablation.
Authors: John R Leyendecker; Gerald D Dodd; Glenn A Halff; Victor A McCoy; Dacia H Napier; Linda G Hubbard; Kedar N Chintapalli; Shailendra Chopra; W Kenneth Washburn; Robert M Esterl; Francisco G Cigarroa; Ruth E Kohlmeier; Francis E Sharkey Journal: AJR Am J Roentgenol Date: 2002-05 Impact factor: 3.959
Authors: J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés Journal: J Hepatol Date: 2001-09 Impact factor: 25.083
Authors: Andrew C Larson; Thomas K Rhee; Jie Deng; Dingxin Wang; Kent T Sato; Riad Salem; Tatjana Paunesku; Gayle Woloschak; Mary F Mulcahy; Debiao Li; Reed A Omary Journal: J Magn Reson Imaging Date: 2006-07 Impact factor: 4.813
Authors: Dingxin Wang; Affaan K Bangash; Thomas K Rhee; Gayle E Woloschak; Tatjana Paunesku; Riad Salem; Reed A Omary; Andrew C Larson Journal: Radiology Date: 2007-10 Impact factor: 11.105
Authors: Ilya L Gubskiy; Daria D Namestnikova; Veronica A Revkova; Elvira A Cherkashova; Kirill K Sukhinich; Mikhail M Beregov; Pavel A Melnikov; Maxim A Abakumov; Vladimir P Chekhonin; Leonid V Gubsky; Konstantin N Yarygin Journal: Biomedicines Date: 2022-02-01